This elucidation suggests that circMETTL3 level could serve as a diagnosis biomarker for CRC and targeting RUNX3/circMETTL3/miR-107/PER3 axis might be an avenue to treat CRC. Here, RUNX3 is linked to colorectal carcinoma.